Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

JJDC buys $33mm in Bavarian Nordic equity

22 Aug 2017

Executive Summary

Johnson & Johnson's Johnson & Johnson Development Corp. purchased $32.8mm (DKK207.5mm) new Bavarian Nordic AS stock in a private placement of 512,102 shares priced at $64.18. As a result, JJDC now holds 1,844,086 shares in Bavarian Nordic corresponding to 5.77% of the share capital and voting rights. The financing is part of a concurrent deal between Bavarian Nordic and J&J's Janssen Pharmaceuticals Inc. subsidiary in which Janssen received exclusive global rights to use MVA-BN technology to develop vaccines for hepatitis B virus and HIV.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By